Scientific Abstract 
This is phase I/ll pilot project will evaluate the survival, tolerance, safety, and efficacy of 
infusions of activated, gene marked, syngeneic T lymphocytes obtained from HIV 
seronegative identical twins on the functional immune status of HIV infected twin 
recipients. T cells from each seronegative twin will be obtained by periodic apheresis, 
separated into CD4 and CD8 enriched populations by monoclonal antibody affinity 
techniques, induced to polyclonal proliferation with anti-CD3 and rlL-2 stimulation, 
transduced with distinctive NeoR retroviral vectors, and expanded 10-1000-fold during 
approximately 2 weeks in tissue culture. The marked T cell populations will then be 
infused into the HIV infected twin and the survival of the uniquely marked T cells will 
be monitored by vector specific PCR, while the HIV infected recipient’s functional 
immune status will be monitored by standard in vitro and in vivo tests. A total of 3 
treatments will be given at intervals of 6 weeks to each patient. 
Non-technical Abstract 
HIV infection cripples a person’s immune system, especially his T lymphocytes. This 
study will see if transferring healthy T lymphocytes which are immunologically 
matched with the patient will help the immune system of the HIV infected person. 
Lymphocytes from the blood of an HIV noninfected identical twin will be removed in a 
manner similar to blood donation. They will be grown in a tissue culture laboratory for 
1 to 2 weeks. During this time they will be activated with OKT3 which is a monoclonal 
antibody and IL-2 which is a hormone of the immune system. They will also be 
separated into two populations: helper cells (CD4) and effecter cells (CD8). They will 
also be treated with a modified retrovirus that contains a gene sequence that will 
uniquely identify the cells’ DNA. This retrovirus is not like HIV, nor can it spread from 
cell to cell. It will not produce an infection. The purpose of the gene insertion with the 
retrovirus is to be able to find and identify the donor’s cells after after they have been 
infused into the HIV infected recipient. The gene transfer will not make the transfused 
lymphocytes more effective. After the cells are grown and treated they will be infused 
into the HIV infected twin. Each patient will have 3 treatments separated by 6 weeks. 
Periodically the HIV infected twin will have tests of his immune system to see if the 
transfused cells are helping. In addition, special tests (called PCR) will be done on the 
DNA from his blood lymphocytes to see if the transfused cells are still present in the 
circulation, to learn how long they will circulate, and to see if there is a difference in the 
survival of the helper and effecter lymphocytes.. 
Recombinant DNA Research, Volume 16 
[327] 
